Literature DB >> 8748759

Tumour response and morphological changes of acoustic neurinomas after radiosurgery.

V Valentino1, A J Raimondi.   

Abstract

Twenty-seven of the 1560 patients treated by radiosurgery during the period 1984-1993 had acoustic neurinomas. Four cases were excluded from this study because they had a follow-up of less than 2 years. There were 24 neurinomas treated in 23 patients as one patient had a bilateral tumour. Seven patients underwent radiosurgery for a recurrent tumour (already operated on once or twice), while it was the first treatment for 16 patients. The tumour volume ranged from 1.99 cm3 to 18.30 cm3, and the patient follow-up was from 2 to 8 years. To determine the target on CT/NMR for linear accelerator stereotactic irradiation, the Greitz-Bergström non-invasive head fixation device was used. It was again adopted for subsequent serial imaging, and for repeat radiosurgery when necessary. The total peripheral tumour dose ranged from 12 to 45 Gy. In 9 patients there was a reduction in tumour volume varying from 39 to 100%, while 14 of the neurinomas appeared stable after an average follow-up of 3 years. In one patient there was an increase in size of the tumour. Variable morphological changes were present in 66% of the neurinomas treated. Radiosurgery is indicated as an alternative to microsurgery for inoperable patients and for those who refuse surgery, for recurrent tumours, and as a post-operative complementary treatment for partially removed tumours. A gradual approach to radiosurgery, depending on tumour response, allows a greater efficacy with minimal risk. In the present series no complications were observed. Hearing was preserved at almost the same level as that prior to radiosurgery in all patients.

Entities:  

Mesh:

Year:  1995        PMID: 8748759     DOI: 10.1007/bf01420067

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  9 in total

1.  Acoustic neuroma--the patient's perspective: subjective assessment of symptoms, diagnosis, therapy, and outcome in 541 patients.

Authors:  D A Wiegand; V Fickel
Journal:  Laryngoscope       Date:  1989-02       Impact factor: 3.325

2.  Head fixation system for integration of radiodiagnostic and therapeutic procedures.

Authors:  T Greitz; M Bergström; J Boëthius; D Kingsley; T Ribbe
Journal:  Neuroradiology       Date:  1980       Impact factor: 2.804

Review 3.  Vestibular schwannoma (acoustic neuroma). Consensus development conference.

Authors:  R Eldridge; D Parry
Journal:  Neurosurgery       Date:  1992-06       Impact factor: 4.654

4.  Gamma knife surgery in acoustic tumours.

Authors:  G Norén; D Greitz; A Hirsch; I Lax
Journal:  Acta Neurochir Suppl (Wien)       Date:  1993

5.  The results of radiosurgical management of 72 middle fossa meningiomas.

Authors:  V Valentino; G Schinaia; A J Raimondi
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

6.  Radiosurgery of acoustic neurinomas.

Authors:  J C Flickinger; L D Lunsford; R J Coffey; M E Linskey; D J Bissonette; A H Maitz; D Kondziolka
Journal:  Cancer       Date:  1991-01-15       Impact factor: 6.860

7.  Stereotactic radiosurgery in cases of acoustic neurinoma: further experiences.

Authors:  G Norén; J Arndt; T Hindmarsh
Journal:  Neurosurgery       Date:  1983-07       Impact factor: 4.654

8.  Volume growth rate of acoustic neurinomas.

Authors:  E M Laasonen; H Troupp
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

9.  Hearing preservation in acoustic tumour surgery.

Authors:  M Samii; C Matthies
Journal:  Adv Tech Stand Neurosurg       Date:  1995
  9 in total
  2 in total

1.  Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

Authors:  Susan C Pannullo; Justin F Fraser; Jennifer Moliterno; William Cobb; Philip E Stieg
Journal:  J Neurooncol       Date:  2010-12-09       Impact factor: 4.130

2.  Tumor pseudoprogression following radiosurgery for vestibular schwannoma.

Authors:  Caroline Hayhurst; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2011-10-25       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.